NeuraLight presents at the International Parkinson and Movement Disorder Society (MDS) Congress 2023

NeuraLight participated in the International Parkinson and Movement Disorder Society (MDS) Congress 2023, presenting new results on “Correlation between oculometric measures, disease severity, and clinical assessment in patients with Parkinson’s disease”, emphasising the role of oculometric biomarkers in Parkinson’s disease.

Key Details

• Findings: Eye-movement–derived metrics correlated with established clinical scales, supporting their potential as objective biomarkers for disease severity and progression.
• Approach: NeuraLight’s software-based platform analyzed subtle ocular signatures from standard video, offering reproducible and non-invasive measurements.

Significance

The results reinforce NeuraLight’s vision of advancing objective, sensitive, and scalable biomarkers for neurological diseases. By demonstrating correlation with gold-standard clinical measures, this study highlights how oculometrics can strengthen trial design and patient monitoring in Parkinson’s disease.

Learn more about the MDS Congress here.